Quote:• Nealy all patents showed decline of ctDNA at week 2
• Median decrease ctDNA 350 mg Leronlimab cohort 70%
• Median decrease ctDNA 700 mg Leronlimab 90%
This was from Dr. J's presentation, with n=23 patients with available ctDNA data.
Hoffman's presentation included 5 additional patients (n=28) and median decrease in ctDNA 350 mg cohort increased to 80%.
Is the dose response becoming less apparent?
My guess is the n=28 is all City of Hope patients as Dr. Kasi was the one tracking ctDNA levels. Hopefully the Natera data for all remaining patients will be available at ESMO.